SCHEMBL20137089

SCHEMBL20137089

O=Cc1ccc(C(F)(F)F)cc1N(CCCC(=O)O)Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
NR1H2 P55055 2/20 0.38
NR1H3 Q13133 2/20 0.38
CYSLTR2 Q9NS75 1/20 0.38
CYSLTR1 Q9Y271 1/20 0.38
PPARG P37231 3/20 0.38
PPARA Q07869 3/20 0.38
PPARD Q03181 2/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MTOR P42345 1/20 0.37
FFAR2 O15552 1/20 0.36
CETP P11597 1/20 0.36
NR3C1 P04150 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29561187 1.00 FFAR4 (0.39) FFAR4MEN1KMT2ATMEM97SIGMAR1
Hydrochloric Acid SCHEMBL29560707 0.99 FFAR4 (0.39) FFAR4MEN1KMT2ATMEM97SIGMAR1
Hydrochloric Acid SCHEMBL20137048 0.99 FFAR4 (0.39) FFAR4MEN1KMT2ATMEM97SIGMAR1
Trifluoroacetic Acid SCHEMBL29561105 0.98 PPARG (0.39) FFAR4MEN1KMT2ATMEM97SIGMAR1
SCHEMBL20570505 0.88 LTB4R2 (0.42) NR1H2PPARGPPARAPPARD
SCHEMBL20137037 0.87 KDM4E (0.38) MEN1KMT2ATMEM97SIGMAR1NR1H2
Hydrochloric Acid SCHEMBL20137043 0.86 KDM4E (0.37) MEN1KMT2ATMEM97SIGMAR1NR1H2
SCHEMBL20158307 0.86 CETP (0.40) MEN1KMT2ATMEM97SIGMAR1NR1H2
SCHEMBL28322495 0.85 MEN1 (0.40) FFAR4MEN1KMT2ATMEM97SIGMAR1
SCHEMBL20137009 0.84 MGLL (0.36) MEN1KMT2ATMEM97SIGMAR1NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110267963-B MAGL inhibitors H.隆德贝克有限公司 2022-04-01 CN disclosed
EP-3541821-A1 MAGL INHIBITORS Abide Therapeutics, Inc. (US) 2019-09-25 EP disclosed
US-10093635-B2 MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2018-10-09 US disclosed
WO-2018093947-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 WO disclosed
WO-2018093947-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 WO disclosed
US-20180134674-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-05-17 US disclosed
US-20180134674-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134674-A1 MAGL INHIBITORS MAG, MAGI3, MGLL FFAR4 3652/4885MEN1 2056/4885KMT2A 2263/4885
US-10093635-B2 MAGL inhibitors MAG, MAGI3, MGLL FFAR4 3652/4885MEN1 2056/4885KMT2A 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.